Spherix Incorporated , an intellectual property company, owns, develops, acquires, and monetizes patented and unpatented intellectual properties. The company owns approximately 290 patents and patent applications. Its patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular. Spherix Incorporated was founded in 1967 and is based in New York, New York.

  • Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
    on May 16, 2019 at 12:00 pm

    Agreement to Acquire Assets of CBM BioPharma, Inc. In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation.  The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future. […]

  • SmallCap Sentinel: One-on-One with Spherix CEO, Anthony Hayes
    on April 10, 2019 at 11:00 am

    ORLANDO, FL / ACCESSWIRE / April 10, 2019 / In today's issue of SmalCap Sentinel, we get the opportunity to virtually sit down with Spherix Incorporated (SPEX) CEO, Anthony Hayes. It has been an eventful year for Hayes and Spherix, much of which Hayes covered in a wide-ranging recent shareholderletter. […]

  • Emerging Markets Report: By Any Measure
    on April 3, 2019 at 3:40 pm

    ORLANDO, FL / ACCESSWIRE / April 3, 2019 / By any measure, Spherix Incorporated (NASDAQ: SPEX) has had a very good year. It is not often one can say at their annual meeting that the Company posted a one-time gain of $7.5 million and p.s., our science looks like it restored mobility to a mouse paralyzed by Acute Lymphoblastic Leukemia. With Spherix now booking total assets of $13.3 million, less than 9 million shares outstanding and zero debt, CEO Anthony Hayes has likely engendered some goodwill from his shareholder base. […]

  • Spherix Issues Letter to Shareholders
    on April 2, 2019 at 12:00 pm

    One of the most challenging tasks as CEO is taking the vision of the Board and transferring that into meaningful value for our shareholders.  However, 2018 marked a pivotal year for our Company as we forged ahead with the vision of creating an exciting biotechnology company.  With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction. The CBM transaction, announced in October of last year, brings to Spherix exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.  Significant progress has already been made. […]

  • SmallCap Sentinel: A Gain of Uncommon Proportions
    on March 13, 2019 at 3:20 pm

    ORLANDO, FL / ACCESSWIRE / March 13, 2019 / In the world of smaller equities, revenue, especially for emerging biotech or tech companies, can be fleeting, rare even. As such, Spherix Incorporated (SPEX) posting a one-time gain of $7.5 million in its 10-K should turn a few heads. It is notable that the $7.5 million one-time gain comes from an investment the Company and Spherex CEO Anthony Hayes made two years ago, putting $670k into a then private biotech called Hoth Therapeutics where Hayes saw potential and promise. […]

  • Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain
    on March 12, 2019 at 12:00 pm

    NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual ... […]

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    on March 8, 2019 at 10:08 pm

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been activ […]

  • Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward
    on November 27, 2018 at 1:00 pm

    NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA).  PDA is considered the deadliest of major cancers and patients are in desperate need of improved therapies. PDA is caused by chronic inflammatory stress associated with the increasingly common afflictions of obesity, type 2 diabetes, and pancreatitis, exacerbated by smoking and drinking.  KPC34 is a candidate therapeutic because it is activated preferentially inside tumor cells to release an inhibitor of DNA replication and a separate tumor promotion inhibitor. Annually, more than 350,000 new cases of pancreatic cancer are diagnosed across the world.  According to the American Society of Clinical Oncology, a six-month course of gemcitabine, the chemotherapy drug typically used to treat advanced pancreatic cancer, costs about $23,500. […]

  • Today's Research Reports on Trending Tickers: Twilio and Spherix
    on November 27, 2018 at 11:55 am

    NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Twilio shares were on the rise on an “outperform” rating reiterated from an Oppenheimer analyst last week while Spherix Incorporated shares popped on news ... […]

  • Spherix Announces Ownership Interest in Electric Scooter Business
    on November 26, 2018 at 1:20 pm

    From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission. […]


What's Your Role?*



Company Description*



Spherix Incorporated

One Rockefeller Plaza
11th Floor
New York, NY 10020

+1 (703) 992-9325


May 2019
« Apr    

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account